• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
CADTH_2014_E4_Is_HTA_More_Similar_Than_Different_Across_the_Atlantic__Is there room for collaboration__Ansgar Hebborn
 

CADTH_2014_E4_Is_HTA_More_Similar_Than_Different_Across_the_Atlantic__Is there room for collaboration__Ansgar Hebborn

on

  • 148 views

Is HTA More similar Than Different Across the Atlantic? Comparison of Canada and Europe

Is HTA More similar Than Different Across the Atlantic? Comparison of Canada and Europe

Statistics

Views

Total Views
148
Views on SlideShare
148
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    CADTH_2014_E4_Is_HTA_More_Similar_Than_Different_Across_the_Atlantic__Is there room for collaboration__Ansgar Hebborn CADTH_2014_E4_Is_HTA_More_Similar_Than_Different_Across_the_Atlantic__Is there room for collaboration__Ansgar Hebborn Presentation Transcript

    • Is HTA more similar than different across the Atlantic? Is there room for collaboration? Ansgar Hebborn F. Hoffmann-La Roche AG, Basel, Switzerland Ottawa, CADTH Conference, 8 April 2014
    • How similar is HTA between jurisdictions? The value proposition of multi-stakeholder HTA collaboration Recommendations
    • From a distance it all looks very similar Relative effectiveness research principles 3 Kleijnen, S. et al. Relative effectiveness assessments of pharmaceuticals, Value Health 2012
    • Similar, but certainly not the same Kleijnen et al. : EUnetHTA JA WP5: Relative Effectiveness Assessment (REA) of Pharmaceuticals. Background review 2011.
    • HTA objectives impact principles and conduct Germany: HTA with sole focus on price negotiations 5
    • HTA submission requirements & templates EUnetHTA analysis George E., BDA 2014
    • HTA submission requirements & templates EUnetHTA analysis George E., BDA 2014
    • George E., BDA 2014
    • How similar is HTA between jurisdictions? The value proposition of multi-stakeholder HTA collaboration Recommendations
    • Multi-stakeholder REA collaboration Aligning national assessments - a realistic expectation? HTA Country A Ethical/legal/ social impact Cost vs benefit and budget impact HTA Country B Ethical/legal/ social impact Cost vs benefit and budget impact HTA Country Z Ethical/legal/ social impact Cost vs benefit and budget impact o o o Relative clinical effectiveness Relative clinical effectiveness Relative clinical effectiveness Efficacy Safety Quality Evidence Base Development (Manufacturer) EMA Methodological Standard EMA Joint Methodological Standards (HTA) Joint Regulatory Assesment ? Alignment?
    • 11 Multi-stakeholder REA collaboration Key pillars of its value proposition Faster and more consistent patient access by means of: – a common set of “reasonable” evidentiary and analytical standards i.e. to balance relevance, validity, feasibility, and timeliness, based on a thorough understanding of the “real of world” of technology development and its challenges – improved process efficiency: avoiding unnecessary duplication of effort in HTA agencies and companies
    • How similar is HTA between jurisdictions? The value proposition of multi-stakeholder HTA collaboration Recommendations
    • Multi-stakeholder REA collaboration Recommendations 1. Clarify objectives, develop compelling “value proposition” for stakeholders, understand supportive forces of collaboration (incentives/disincentives) 2. Seek political support at home – to secure resources required for collaboration – to overcome legal constraints to use jointly developed assessments down stream to ultimately realize process efficiencies 3. Focus on areas that are the least specific to the local context – General methodological standards for REA – Disease-specific REA guidance – Product-specific early dialogue/scientific advice – Joint REAs
    • Doing now what patients need next